Current Realities of Make vs. Buy For Advanced Therapies in Manufacturing

11:00 AM - 12:00 PM (PDT), Wednesday, June 15, 2022

This panel of leading industry experts will discuss key considerations and experiences related to the Make vs. Buy decision from a variety of perspectives. Speakers will debate whether those considerations are unique to today’s environment and how they might be different in the future. How have the supply chain disruptions post-pandemic affected production? Has prioritization of vaccine manufacturing been a benefit or a challenge to other therapeutic production? What is the impact of de-risking innovative technologies to improve biologics manufacturing in the future? This session will solicit significant audience input to shape the discussion.

Moderator
photo
Sr Director, R&D Projects
Thermo Fisher Scientific
Speakers
photo
Technical Head, Gene Therapy
Resilience
photo
Director Search Strategy Evaluation Gene, Cell & Nucleic Acids
Cytiva
photo
Global Head of Product Development, Cell and Gene Therapy
Catalent Biologics